Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308766 | 1.00 | FOLH1 (0.58) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29371190 | 1.00 | FOLH1 (0.58) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29617647 | 1.00 | FOLH1 (0.58) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29860303 | 0.97 | FOLH1 (0.55) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29759596 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL1243885 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL1243890 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL30584460 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL23876142 | 0.95 | FOLH1 (0.51) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL21645322 | 0.95 | FOLH1 (0.51) | FOLH1GSRGNPATCPB2ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028898-A | Novel short-chain peptides and derivatives thereof | 艾缇亚(上海)制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2025087269-A1 | NEW SHORT-CHAIN PEPTIDES AND DERIVATIVES THEREOF | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-05-01 | — | — | WO | claimed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | claimed |
| WO-2023139106-A2 | LONG-ACTING GIPR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | claimed |
| WO-2023003984-A2 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-26 | — | — | WO | claimed |
| CN-109475483-B | Aspartyl dipeptides for skin care and cosmetic use | 凯塞尔德国有限公司 | 2022-06-14 | — | — | CN | claimed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| CN-113057265-A | Feed additive for coilia ectenes juvenile fish and preparation method thereof | 浙江省海洋水产研究所 | 2021-07-02 | — | — | CN | claimed |
| EP-3829617-A1 | COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION | Cysal GmbH (DE) | 2021-06-09 | — | — | EP | claimed |
| WO-2020025656-A1 | COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION | CYSAL GMBH (DE) | 2020-02-06 | — | — | WO | claimed |
| CN-120064628-B | Metabolic marker for evaluating operation prognosis of hypertrophic cardiomyopathy patient and application | 中国医学科学院阜外医院 | 2026-05-22 | — | — | CN | disclosed |
| CN-122028898-A | Novel short-chain peptides and derivatives thereof | 艾缇亚(上海)制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| WO-2002082047-A2 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6180771-B1 | GIVEN NUCLEOTIDE SEQUENCE; USEFUL FOR PHARMACEUTICAL ADMINISTRATION OR METHODS OF DIAGNOSING SENSITIVITY TO HOUSE DUST MITES | IMMULOGIC PHARMACEUTICAL CORP. | 2001-01-30 | — | — | US | disclosed |
| EP-0733064-A1 | NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, $i(DER P) III, AND USES THEREFOR | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015976-A1 | NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, DER P III, AND USES THEREFOR | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| US-4256632-A | ANTICAREINOGENIC AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | FOLH1 433/4885GSR 1829/4885GNPAT 1219/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | FOLH1 1212/4885GSR 3074/4885GNPAT 1000/4885 |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, MALT1, LY6K | FOLH1 942/4885GSR 4838/4885GNPAT 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.